MiR-6511b-5p Suppresses Metastasis of PMMR Colorectal Cancer Through Methylation of CD44 by Directly Targeting BRG1

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2022 May 19

PMID 35590122

Authors

Jinming Sun

Ling Ye

Yuan Shi

Xingwei Wang

Xiafei Zhao

ShengYong Ren

Junwei Fan

Huanzhang Shao

Bingyu Qin

Affiliations

Soon will be listed here.

Abstract

Purpose: Distal metastases are a major cause of poor prognosis in colorectal cancer patients. Approximately 95% of metastatic colorectal cancers are defined as DNA mismatch repair proficient (pMMR). Our previous study found that miR-6511b-5p was downregulated in pMMR colorectal cancer. However, the mechanism of miR-6511b-5p in pMMR colorectal cancer metastases remain unclear.

Methods: We first used quantitative real-time PCR to evaluate the role of miR-6511b-5p in colorectal cancer. Second, we conducted invasion assays and wound healing assays to investigate the role of miR-6511b-5p and CD44 in colorectal cancer cells metastases. Third, luciferase reporter assay, in situ hybridization (ISH), and immunohistochemistry assays were performed to study the relationship between miR-6511b-5p and BRG1. Finally, real-time quantitative PCR, immunohistochemistry, and chromatin immunoprecipitation (ChIP) assays were performed to analyze the relationship between BRG1 and CD44 in colorectal cancer.

Results: We found that lower expression of miR-6511b-5p appeared more often in pMMR colorectal cancer patients compared with dMMR (mismatch repair deficient) cases, and was positively correlated with metastases. In vitro, overexpression of miR-6511b-5p inhibited metastasis by decreasing CD44 expression via directly targeting BRG1 in colorectal cancer. Furthermore, BRG1 knockdown decreased the expression of CD44 by promoting CD44 methylation in colorectal cancer cells.

Conclusion: Our data suggest that miR-6511b-5p may act as a promising biomarker and treatment target for pMMR colorectal cancer, particularly in metastatic patients. Mechanistically, miR-6511b-5p suppresses invasion and migration of colorectal cancer cells through methylation of CD44 via directly targeting BRG1.

Citing Articles

Moxibustion Regulates the BRG1/Nrf2/HO-1 Pathway by Inhibiting MicroRNA-222-3p to Prevent Oxidative Stress in Intestinal Epithelial Cells in Ulcerative Colitis and Colitis-Associated Colorectal Cancer.

Wang X, Ji H, Yang Y, Zhang D, Kong X, Li X J Immunol Res. 2024; 2024:8273732.

PMID: 39359694 PMC: 11446618. DOI: 10.1155/2024/8273732.

The GJB3 correlates with the prognosis, immune cell infiltration, and therapeutic responses in lung adenocarcinoma.

Dou R, Liu R, Su P, Yu X, Xu Y Open Med (Wars). 2024; 19(1):20240974.

PMID: 39135979 PMC: 11317640. DOI: 10.1515/med-2024-0974.

Mutual Regulation of ncRNAs and Chromatin Remodeling Complexes in Normal and Pathological Conditions.

Bure I, Nemtsova M Int J Mol Sci. 2023; 24(9).

PMID: 37175555 PMC: 10178202. DOI: 10.3390/ijms24097848.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Van Cutsem E, Nordlinger B, Adam R, Kohne C, Pozzo C, Poston G . Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006; 42(14):2212-21. DOI: 10.1016/j.ejca.2006.04.012. View

Hewish M, Lord C, Martin S, Cunningham D, Ashworth A . Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010; 7(4):197-208. DOI: 10.1038/nrclinonc.2010.18. View

Wheeler J, Bodmer W, Mortensen N . DNA mismatch repair genes and colorectal cancer. Gut. 2000; 47(1):148-53. PMC: 1727951. DOI: 10.1136/gut.47.1.148. View

Carethers J, Jung B . Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology. 2015; 149(5):1177-1190.e3. PMC: 4589489. DOI: 10.1053/j.gastro.2015.06.047. View

Tejpar S, Saridaki Z, Delorenzi M, Bosman F, Roth A . Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst. 2011; 103(11):841-4. DOI: 10.1093/jnci/djr170. View

Havel J, Chowell D, Chan T . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019; 19(3):133-150. PMC: 6705396. DOI: 10.1038/s41568-019-0116-x. View

Ganesh K, Stadler Z, Cercek A, Mendelsohn R, Shia J, Segal N . Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019; 16(6):361-375. PMC: 7295073. DOI: 10.1038/s41575-019-0126-x. View

Gregory R, Shiekhattar R . MicroRNA biogenesis and cancer. Cancer Res. 2005; 65(9):3509-12. DOI: 10.1158/0008-5472.CAN-05-0298. View

10.

Liao T, Cheng W, Yang C, Chen Y, Su S, Yeh T . The microRNA-210-Stathmin1 Axis Decreases Cell Stiffness to Facilitate the Invasiveness of Colorectal Cancer Stem Cells. Cancers (Basel). 2021; 13(8). PMC: 8069838. DOI: 10.3390/cancers13081833. View

11.

Ning T, Li J, He Y, Zhang H, Wang X, Deng T . Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. Mol Ther. 2021; 29(9):2723-2736. PMC: 8417448. DOI: 10.1016/j.ymthe.2021.04.028. View

12.

Mao G, Lee S, Ortega J, Gu L, Li G . Modulation of microRNA processing by mismatch repair protein MutLα. Cell Res. 2012; 22(6):973-85. PMC: 3367530. DOI: 10.1038/cr.2012.18. View

13.

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F . Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107(15):6982-7. PMC: 2872463. DOI: 10.1073/pnas.1002472107. View

14.

Ye L, Jiang T, Shao H, Zhong L, Wang Z, Liu Y . miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2. Mol Ther Nucleic Acids. 2017; 7:453-464. PMC: 5443909. DOI: 10.1016/j.omtn.2017.05.006. View

15.

Thorne R, Wang Y, Zhang Y, Jing X, Zhang X, de Bock C . Evaluating nuclear translocation of surface receptors: recommendations arising from analysis of CD44. Histochem Cell Biol. 2019; 153(2):77-87. DOI: 10.1007/s00418-019-01835-y. View

16.

Ponta H, Sherman L, Herrlich P . CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4(1):33-45. DOI: 10.1038/nrm1004. View

17.

Cho S, Park Y, Kim H, Kim C, Lim S, Huh J . CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 2012; 41(1):211-8. DOI: 10.3892/ijo.2012.1453. View

18.

Strobeck M, Decristofaro M, Banine F, Weissman B, SHERMAN L, Knudsen E . The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J Biol Chem. 2000; 276(12):9273-8. DOI: 10.1074/jbc.M009747200. View

19.

Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen E . SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res. 2005; 65(9):3542-7. DOI: 10.1158/0008-5472.CAN-04-3554. View

20.

Lin S, Jiang T, Ye L, Han Z, Liu Y, Liu C . The chromatin-remodeling enzyme BRG1 promotes colon cancer progression via positive regulation of WNT3A. Oncotarget. 2016; 7(52):86051-86063. PMC: 5349896. DOI: 10.18632/oncotarget.13326. View